Endologix (ELGX) Tops Q3 EPS by 1c

Go back to Endologix (ELGX) Tops Q3 EPS by 1c

BMO Capital Downgrades Endologix (ELGX) to Market Perform

October 27, 2015 7:09 AM EDT

BMO Capital downgraded Endologix (NASDAQ: ELGX) from Outperform to Market Perform with a price target of $12.00 (from $16.00).

For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.

Shares of Endologix closed at $13.73 yesterday.

... More

Endologix (ELGX), TriVascular (TRIV) Enter Merger Agreement

October 26, 2015 4:03 PM EDT

Endologix (NASDAQ: ELGX) and TriVascular Technologies, Inc. (Nasdaq: TRIV) announced today that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at $9.10 per TriVascular share, or a total of approximately $211 million, based on Endologix's closing stock price of $13.81 per share on October 23, 2015.

John McDermott, Chairman and Chief Executive Officer of Endologix, said, "This merger enhances the near and long-term growth potential of our business by bringing together two of the most innovative... More